Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Graphite Bio, Inc.

Graphite Bio is a clinical-stage, next-generation gene editing company driven to discover and develop cures for a wide range of serious and life-threatening diseases. The company is pioneering a precision gene editing approach that has the potential to transform human health by achieving one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s UltraHDR™ gene editing platform takes CRISPR beyond cutting and harnesses the power of high-efficiency precision DNA repair, also known as homology-directed repair (HDR), to precisely correct genetic mutations, replace entire disease-causing genes with functional genes or insert new genes into predetermined, safe locations. Additionally, the company is advancing the development of novel conditioning regimens to help bring curative therapies to more patients. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.

See our Community Guidelines at bit.ly/3c5Pztz. 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue					2.41M -
gross profit					-2.41M -
selling and marketing expenses
general and administrative expenses	29K -	4.38M 14,993.10%	22.51M 414.30%	32.85M 45.94%	40.97M 24.72%
selling general and administrative expenses	29K -	4.38M 14,993.10%	22.51M 414.30%	32.85M 45.94%	40.97M 24.72%
research and development expenses		9.12M -	37.93M 315.78%	72.79M 91.89%	29.73M 59.15%
other expenses		-54.83M -	-10.32M 81.18%		62.08M -
cost and expenses	29K -	13.50M 46,451.72%	60.44M 347.73%	105.64M 74.77%	73.11M 30.79%
operating expenses	29K -	13.50M 46,451.72%	60.44M 347.73%	105.64M 74.77%	70.70M 33.07%
interest expense	80K -	40K 50%		4.59M -
ebitda	-29K -	-68.21M 235,113.79%	-70.76M 3.74%	-105.64M 49.29%	-70.70M 33.07%
operating income	-29K -	-13.50M 46,451.72%	-60.44M 347.73%	-105.64M 74.77%	-73.11M 30.79%
depreciation and amortization		-54.71M -	-10.32M 81.14%	2.35M 122.80%	2.41M 2.34%
total other income expenses net	-80K -	-54.87M 68,491.25%	-10.32M 81.20%	4.59M 144.46%	-51.54M 1,223.63%
income before tax	-109K -	-68.37M 62,627.52%	-70.76M 3.49%	-101.05M 42.81%	-124.65M 23.35%
income tax expense	80K -	-54.79M 68,591.25%	-11.05M 79.83%	-4.59M 58.49%
net income	-189K -	-13.58M 7,085.19%	-59.71M 339.68%	-96.47M 61.56%	-124.65M 29.22%
weighted average shs out	14.63M -	34.19M 133.71%	28.92M 15.41%	54.87M 89.75%	57.02M 3.90%
weighted average shs out dil	14.63M -	34.19M 133.71%	28.92M 15.41%	54.87M 89.75%	57.02M 3.90%
eps	-0.01 -	-0.40 3,000.78%	-2.06 415.00%	-1.76 14.56%	-2.19 24.43%
epsdiluted	-0.01 -	-0.40 3,000.78%	-2.06 415.00%	-1.76 14.56%	-2.19 24.43%

COM:GRAPHITEBIO

Graphite Bio, Inc.

Last Close

3.27

21/03 20:00

Market Cap

185.19M

Beta: -

Volume Today

299.41K

Avg: -

Preview